Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > JV with Merck's Keyteuda a bad idea...

<< Previous

Bullboard Posts

Next >>

Comment by 2b7f6fabon Dec 18, 2024 1:05pm

186 Views

Post# 36368322

RE:JV with Merck's Keyteuda a bad idea...

Mrk stock chart is not looking too well the past six months. Mrk has 2.53 billion shares outstanding. For just 30 million more shares Mrk could probably acquire TLT. I mean small potatoes difference between 2.56 vs 2.53 billion shares? That gives TLT shareholders $10/share. I wouldn't be complaining.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features